Zocor Offer Draws Predatory Pricing Accusations

Law360, New York (June 22, 2006, 12:00 AM EDT) -- With a generic version of cholesterol drug Zocor hitting shelves today, an offer by Merck & Co. to provide the drug for below the generic price has some accusing the pharmaceutical company of predatory pricing.

Merck offered to sell the brand-name drug to insurance providers at a lower price than Teva Pharmaceuticals, which won the rights to a 180-day period of market exclusivity for a generic version of Zocor.

The insurance provider would in turn offer the drug to patients for the co-payment fee normally charged...
To view the full article, register now.